Clinical trials: Borderline-resectable Pancreatic Cancer
Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer
Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.
Pancreatic ductal adenocarcinoma (PDAC) remains a dreadful disease due to its often advanced stage at diagnosis and poor sensitivity to chemotherapy.
- Trial name
- LAPTOP (NCT04247165)
- Testing
- Gemcitabine, Nab-paclitaxel, Nivolumab
- Where
- Denmark
- Volunteers
- 55 people
- Sponsor
- Herlev Hospital
Pancreatic Cancer Resectable, Pancreatic Cancer Stage II
Neoadjuvant Chemotherapy for Elderly with Pancreatic Head Cancer
The goal of this observational retrospective cohort study is to evaluate the efficacy and safety of neoadjuvant chemotherapy (NAT) in elderly patients with resectable or borderline resectable (BR) pancreatic ductal adenocarcinoma…
- Conditions
- Pancreatic Cancer Resectable, Pancreatic Cancer Stage II, Neoadjuvant Therapy, Elderly
- Trial name
- PEACE (NCT06868693)
- Testing
- Neoadjuvant Chemotherapy (NAT) Group
- Volunteers
- 240 people
- Sponsor
- Azienda Unita Sanitaria Locale di Piacenza
Pancreatic Cancer, Resectable Pancreatic Cancer
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
This study is being done to evaluate the safety and efficacy of adding NIS793 to standard of care FOLFIRINOX treatment for pancreatic cancer.
- Conditions
- Pancreatic Cancer, Resectable Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT05546411
- Testing
- mFOLFIRINOX, 5-Fluorouracil (5-FU), Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Kimberly Perez, MD
Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma
Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC
The goal of this multicenter randomized controlled phase III trial is to compare two durations of neoadjuvant chemotherapy (NAT) with mFOLFIRINOX or gemcitabine-nab-paclitaxel (GnP) before attempt for surgical resection in…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma, Pancreas Cancer, Neoadjuvant Chemotherapy
- Trial name
- ADVANTAGE (NCT06714604)
- Testing
- FOLFIRINOX or gemcitabine-nab-paclitaxel
- Where
- Sweden
- Volunteers
- 432 people
- Sponsor
- Sahlgrenska University Hospital
Borderline Resectable Pancreatic Cancer
Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer
This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of irinotecan liposome II in combination with oxaliplatin and 5-FU/LV in perioperative treatment of borderline resectable pancreatic cancer in…
- Trial name
- undetermined (NCT06387810)
- Testing
- irinotecan liposome II combined with 5-FU/LV and oxaliplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Peking Union Medical College Hospital
SBRT, Borderline Resectable Pancreatic Cancer
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
GTI-4711-201 is designed as a Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the effect to OS by adding GC4711 to SBRT following chemotherapy in patients with unresectable or borderline…
- Conditions
- SBRT, Borderline Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer
- Trial name
- NCT04698915
- Testing
- Drug GC4711
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 177 people
- Sponsor
- Galera Therapeutics, Inc.
Borderline Resectable Pancreatic Cancer
IORT on Borderline Resectable Pancreatic Cancer
This phase II study investigates the efficacy of IORT for patients with borderline resectable pancreatic cancer. The purpose of the study is to investigate whether the addition of IORT, after FOLOFIRINOX-base chemotherapy, and…
- Trial name
- PancFORT (NCT04090463)
- Testing
- Intraoperative radiotherapy
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Universita di Verona
Borderline Resectable Pancreatic Cancer
NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study
The aim of this study is to assess the efficacy and safety of Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab for patients with borderline resectable pancreatic cancer
- Trial name
- NCT06345300
- Testing
- Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab, Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Pancreatic Neoplasm, Pancreatic Adenocarcinoma
Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Surgical resection is the only potentially curative treatment for patients with pancreatic cancer with the aim of curative R0 resection and related improvement of survival.
- Conditions
- Pancreatic Neoplasm, Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
- Trial name
- STEREOPAC (NCT05083247)
- Testing
- mFOLFIRINOX or Gemcitabine nab-paclitaxel, Isotoxic High-Dose (iHD)-SBRT, Surgery
- Where
- 10 sites in Belgium
- Volunteers
- 256 people
- Sponsor
- Erasme University Hospital
Borderline Resectable Pancreatic Cancer
Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC
The aim of this study is to evaluate the safety and efficacy of laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer
- Trial name
- NCT04855331
- Testing
- Laparoscopic pancreatoduodenectomy, Open pancreatoduodenectomy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Pancreas Cancer, Pancreas Neoplasm
Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer
This study aims to assess overall survival, quality of life and resection rates in locally advanced pancreatic cancer
- Conditions
- Pancreas Cancer, Pancreas Neoplasm, Pancreas Disease, Pancreas Adenocarcinoma
- Trial name
- SQUARE (NCT05356039)
- Where
- Sweden
- Volunteers
- 300 people
- Sponsor
- Umeå University
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer
This phase I trial studies the side effects and best dose of nab-paclitaxel when given together with capecitabine and radiation therapy following first treatment with chemotherapy (induction therapy) in treating patients with…
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT02394535
- Testing
- Capecitabine, Laboratory Biomarker Analysis, Nab-paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Histologically or Cytologically Confirmed Pancreatic Cancer, Unresectable or Borderline Resectable Pancreatic Cancer
Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer
Background: Fewer than 10 percent of people with pancreas cancer can have surgery. Surgery gives the best outcome. Radiation therapy is usually used to make surgery possible. But it does not work for most people.
- Conditions
- Histologically or Cytologically Confirmed Pancreatic Cancer, Unresectable or Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Cancer
- Trial name
- NCT04327986
- Testing
- M7824, M9241, SBRT
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer
This is a prospective, single-center, randomized, controlled phase Ⅲ study.
- Trial name
- NCT04617821
- Testing
- Nab paclitaxel plus gemcitabine, mFOLFIRINOX
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Borderline Resectable Pancreatic Cancer
Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer
The aim of this study is to clarify the efficacy and safety of neoadjuvant FOLFIRINOX and nab-paclitaxel + gemcitabine for borderline resectable pancreatic cancer.
- Trial name
- NCT02717091
- Testing
- FOLFIRINOX, gemcitabine + nab-paclitaxel
- Volunteers
- 50 people
- Sponsor
- Nagoya University
Borderline Resectable Pancreatic Cancer
Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer
This study was a single-arm multicenter prospective phase II clinical study, designed to evaluate the efficacy and safety of neoadjuvant nab-paclitaxel combined with S-1 in patients with borderline resectable pancreatic cancer.
- Trial name
- NCT03850769
- Testing
- nab-paclitaxel and S-1
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Histologically or Cytologically Confirmed Pancreatic Ca, Unresectable or Borderline Resectable Pancreatic Ca
Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
Background: Pancreatic cancer is difficult to treat because by the time most cases are diagnosed, the tumors are too large to be removed surgically.
- Trial name
- NCT01294358
- Testing
- Gemcitabine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Patients With Borderline Resectable Pancreatic Cancer
Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study
FOLFIRINOX regimen was recently presented at an international oncology meeting and represents a new standard regimen in the treatment of metastatic pancreatic cancer.
- Trial name
- FIRINOX (NCT02148549)
- Testing
- FIRINOX
- Where
- 9 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Wakayama Medical University
Borderline Resectable Pancreatic Cancer
Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
This is a prospective, randomized phase II trial. Patients diagnosed with borderline resectable pancreatic adenocarcinoma will be randomly assigned to one of two treatment arms, either mFOLFIRINOX or gemcitabine and…
- Trial name
- NCT02241551
- Testing
- gemcitabine/nab-paclitaxel, mFOLFIRINOX
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Nathan Bahary, MD
Pancreatic Cancer, Locally Advanced Pancreatic Cancer
Divestment for Artery-involved Pancreatic Cancer
Pancreatic cancer is the most lethal malignancy of human being. Surgery is the only potential cure of pancreatic cancer. The invasion of major abdominal arteries is one of the most important factor restricting surgical…
- Conditions
- Pancreatic Cancer, Locally Advanced Pancreatic Cancer, Neoadjuvant Therapy, Borderline Resectable Pancreatic Cancer
- Trial name
- NCT03443921
- Testing
- Artery Divestment Technique, Nab-paclitaxel
- Where
- China
- Volunteers
- 122 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University